In a recent study, Viking Therapeutics, Inc. presented findings on VK3019, a potential new treatment for weight loss. The study focused on assessing the safety, tolerability, and pharmacokinetics of a single ascending dose of VK3019. This research offers promise in expanding Viking's treatment options for addressing weight loss concerns. The study took place in San Diego on June 24, 2026, showcasing Viking's commitment to advancing innovative solutions. As a clinical-stage company listed on NASDAQ under the ticker symbol VKTX, Viking continues to drive progress in the field of medical research.